chart, page-2254

That's their only core product, why do you think they are pumping it recently......

Respiratory diseases diagnostics house Respiri (ASX:RSH) says it will also benefit from the American Medical Association’s (AMA’s) proposed changes to reimbursement criteria for remote patient monitoring (RPM) programs.

Respiri’s lead product is Wheezo, an app-based device to detect conditions such as asthma and chronic obstructive pulmonary disorder.

As could be expected, Wheezo is part and parcel of the remote patient management revolution.

Buoyed by the expected changes, the US-focused company today released a prezzo, outlining a total addressable market of 50,000 patients within its current client base and a “sales pipeline” of 250,000 patients.

Respiri currently has 29 clients (service providers) across 2435 patient programs.

In a nutshell, reimbursement will be made available for a lower threshold of two days of patient data collected by Wheezo over a 30-day rolling period, compared with 16 days at present.